Methods of treating or preventing osteoporosis and low bone mass

Abstract

The present application provides methods of use, specifically methods of treatment of a disease, disorder, or condition (e.g., a low bone mass condition such as osteoporosis) in a human individual, comprising administration of novel bispecific antibodies that bind to both sclerostin and DKK-1 (e.g., anti-Sclerostin × anti-DKK-1 bispecific antibodies). The present application also provides methods of increasing bone mineral density in a human individual comprising administration of novel anti-Sclerostin × anti-DKK-1 bispecific antibodies. The present application further provides methods of reducing risk of bone fracture (e.g., osteoporotic fracture) in a human individual comprising administration of novel anti-Sclerostin × anti-DKK-1 bispecific antibodies.